For the first time, researchers have systematically connected regulatory approval decisions with actual patient outcomes for cancer drugs, creating a comprehensive dataset that reveals which treatments truly deliver on their promises. A collaboration between Switzerland's regulatory authority (Swissmedic), University Hospital Zurich (USZ), and the University of Zurich (UZH) analyzed approval data and clinical trial information spanning 2001 to 2020, publishing their findings in two international peer-reviewed journals.

The research addresses a critical gap in modern medicine: while new cancer drugs receive regulatory approval based on clinical trial data, there has been limited systematic analysis of whether those trials actually predict real-world benefits for patients. This new structured dataset combines regulatory decisions with clinical outcomes for the first time in Switzerland, providing what researchers call an "essential prerequisite for reliably assessing the true clinical benefit of new drugs and therapies."

What Do the Cancer Drug Findings Actually Show?

The studies reveal that new cancer drugs can extend patient survival and delay disease progression, though the extent varies significantly depending on the type of tumor and the specific treatment. One key finding involves how researchers measure drug effectiveness. Indirect endpoints such as tumor shrinkage or time to disease relapse are increasingly being interpreted in the context of overall survival, which makes these measures more meaningful for future clinical trials and regulatory decisions.

The research also documents a major shift in how cancer trials are designed. Over the two decades studied, clinical trial designs evolved substantially, with biomarkers becoming increasingly important. Biomarkers are biological characteristics that help identify which patients are most likely to benefit from a specific treatment. This shift reflects the growing movement toward precision oncology, where cancer treatments are tailored to individual biological characteristics rather than using a one-size-fits-all approach.

How Are Researchers Using This Data to Improve Cancer Care?

• Regulatory Transparency: By linking approval data with clinical trial outcomes, researchers can now assess whether the evidence supporting drug approvals is robust and whether it translates to meaningful patient benefits in practice.
• Trial Design Evolution: The analysis shows how oncology trials have adapted over 20 years, with growing emphasis on biomarker-driven patient selection and more sophisticated outcome measures that better reflect real-world effectiveness.
• Personalized Treatment Selection: As biomarkers become central to trial design, oncologists can increasingly select cancer therapies based on each patient's individual biological profile rather than relying solely on tumor type or stage.

"This collaboration demonstrates the value of combining regulatory expertise with clinical and scientific perspectives. By systematically linking approval and trial data, we create a stronger foundation for understanding the benefits of new cancer therapies and ultimately for improving patient care," stated the Director of the Clinical Program at the Comprehensive Cancer Center Zurich.

Director, Clinical Program, Comprehensive Cancer Center Zurich

The implications extend beyond Switzerland. Swissmedic, USZ, and UZH plan to continue their collaboration and expand the shared data platform to address future regulatory and scientific questions with greater precision. For patients, this means that new cancer therapies will not only become available more quickly but will also be selected and applied based on increasingly robust evidence about their actual effectiveness.

This research represents a significant step toward closing the gap between how drugs are approved and how well they actually work in clinical practice. By creating the first structured dataset that combines regulatory decisions with clinical outcomes, Swiss researchers have established a model that other countries and institutions may adopt to ensure that cancer patients receive treatments backed by the strongest possible evidence.